Hong Kong Baptist University and Cornell University jointly develop a novel nano-carrier that increases the efficacy of Chinese medicine treatment for breast cancer

HONG KONG SAR – Media OutReach – 11 May 2021 – Researchers from Hong Kong Baptist University (HKBU), in collaboration with Cornell University, have developed a novel targeted therapy for triple-negative breast cancer (TNBC) that uses a specially-designed nano-carrier to deliver the Chinese medicine compound gambogic acid (GA). The invention enhances the anti-cancer effect of GA and reduces its damage to off-target organs. The invention has the potential to become a more effective therapeutic option for TNBC.